Zobrazeno 1 - 10
of 135
pro vyhledávání: '"Checkpoint inhibitor-related pneumonitis"'
Publikováno v:
BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background Checkpoint inhibitor-related pneumonitis (CIP) is a rare but serious complication of immune checkpoint inhibitors (ICIs). While it typically occurs within the first few months of treatment, its onset after ICI discontinuation is r
Externí odkaz:
https://doaj.org/article/4e2e1e50ff714780b86ceabb00d0c5c3
Autor:
Yu Li, Yuxin Jiang, Luyun Pan, Jun Yao, Shuo Liang, Yanjun Du, Dong Wang, Hongbing Liu, Fang Zhang, Qin Wang, Tangfeng Lv, Ping Zhan
Publikováno v:
Thoracic Cancer, Vol 15, Iss 34, Pp 2437-2448 (2024)
Abstract Background Patients with non‐small‐cell lung cancer (NSCLC) receiving immunotherapy face a potential risk of developing checkpoint inhibitor‐related pneumonitis (CIP). However, there is no clear understanding of the specific link betwe
Externí odkaz:
https://doaj.org/article/0749b4ec3dda425d98a61b92ae0f5806
Autor:
Jiaxi Deng, Wenhui Guan, Minjuan Hu, Haiyi Deng, Wenwei Mo, Ru Li, Ni Sun, Chengzhi Zhou, Xinqing Lin
Publikováno v:
BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-7 (2024)
Abstract Background Immune checkpoint inhibitor-related pneumonitis (CIP) stands out as a particularly severe adverse event caused by immune checkpoint inhibitors, with a substantial real-world incidence ranging from 13 to 19%. While systemic cortico
Externí odkaz:
https://doaj.org/article/678fe6471c9b457fb3a0de7034b04838
Publikováno v:
陆军军医大学学报, Vol 46, Iss 15, Pp 1789-1796 (2024)
Objective To investigate the incidence, risk factors, treatment outcomes, and other clinical outcomes of checkpoint inhibitor-related pneumonitis (CIP) in cancer patients treated with PD-1/PD-L1 inhibitors. Methods Clinical data of 1 084 cancer patie
Externí odkaz:
https://doaj.org/article/d918abb345aa4f57b26b735b435dcc14
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundThe advent of immune checkpoint inhibitors (ICIs) has revolutionized the treatment landscape for tumor patients, dramatically improving survival rate. However, patients treated with immunotherapy are inevitably at risk of immune-related adv
Externí odkaz:
https://doaj.org/article/d23cafd72fe64319bc9bc5abc87b7b8d
Publikováno v:
Cancer Medicine, Vol 12, Iss 15, Pp 15998-16010 (2023)
Abstract Objective Immunotherapy extensively treats advanced non‐small‐cell lung cancer (NSCLC). Although immunotherapy is generally better tolerated than chemotherapy, it can cause multiple immune‐related adverse events (irAEs) involving multi
Externí odkaz:
https://doaj.org/article/b5fddd9a867f41449eb0cce72e910dac
Publikováno v:
Zhongliu Fangzhi Yanjiu, Vol 50, Iss 8, Pp 772-776 (2023)
Objective To investigate the correlation of peripheral blood lymphocyte, T-cell, Th-cell, and Ts-cell counts with the development of checkpoint-inhibitor-related pneumonitis in NSCLC. Methods The clinical data of 85 patients with NSCLC treated with i
Externí odkaz:
https://doaj.org/article/04a33d6458bd48c292a908a68583ac00
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
The advent of immune-checkpoint inhibitors (ICIs) has revolutionized the treatment of malignant solid tumors in the last decade, producing lasting benefits in a subset of patients. However, unattended excessive immune responses may lead to immune-rel
Externí odkaz:
https://doaj.org/article/7926c5b0216342d99008b721bd731674
Autor:
Yang Shu, Wei Xu, Rui Su, Pancen Ran, Lei Liu, Zhizhao Zhang, Jing Zhao, Zhen Chao, Guobin Fu
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Immune checkpoint inhibitors (ICIs) modulate the body’s immune function to treat tumors but may also induce pneumonitis. Immune checkpoint inhibitor-related pneumonitis (ICIP) is a serious immune-related adverse event (irAE). Immunotherapy is curre
Externí odkaz:
https://doaj.org/article/497e5d209030414f9b934783b96c2b48
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.